Meningococcal vaccine group B conjugate - Sanofi-Aventis

Drug Profile

Meningococcal vaccine group B conjugate - Sanofi-Aventis

Alternative Names: Group B meningococcal polysaccharide conjugate vaccine - sanofi pasteur

Latest Information Update: 15 Apr 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator sanofi pasteur
  • Class Meningococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Meningococcal group B infections

Most Recent Events

  • 15 Apr 2008 Discontinued - Phase-I for Meningococcal group B infections in France (IM)
  • 26 May 2006 This vaccine is still in active development
  • 21 Jan 2005 Aventis Pasteur is now called sanofi pasteur
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top